{"name":"Zogenix, Inc.","slug":"zogenix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":81690000,"revenueGrowth":498.8,"grossMargin":0,"rdSpend":0,"netIncome":-227413000,"cash":468489000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Oral Risperidone","genericName":"Oral Risperidone","slug":"oral-risperidone","indication":"Schizophrenia","status":"marketed"},{"name":"Risperdal Consta","genericName":"Risperdal Consta","slug":"risperdal-consta","indication":"Schizophrenia","status":"marketed"}]}],"pipeline":[{"name":"Oral Risperidone","genericName":"Oral Risperidone","slug":"oral-risperidone","phase":"marketed","mechanism":"Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder","Behavioral disturbances in dementia"],"catalyst":""},{"name":"Risperdal Consta","genericName":"Risperdal Consta","slug":"risperdal-consta","phase":"marketed","mechanism":"Risperdal Consta is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Bipolar I disorder maintenance treatment"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZ3Q5LUhQYk1xa19iTW53NWpKOU1UQXZRQTdtMUZnVG9oeGpEQ25STXdhOU1vSFIxQllPbTdSVkpGc0hoNTl5d2w2LVE5WWJVb1JCSUtvZlg1aTBLd2o3allLMHNKQVFyMlVxejVodU9CY0ZYdnBnX1BwX1hlOWlFbjlFR0pxeENibGptZ29OR1VpOVFaQzQ1VWI5V25hc1czS0hQTk9Ld3hNOGJaUFhHNFdNWTh1b2dHV0MtaXpQZHUwTHA4aFpZQXRsTG9KR3p0RTlUSFJlZmRDTGkxRW1xZw?oc=5","date":"2025-06-13","type":"pipeline","source":"Citeline News & Insights","summary":"UCB Follows Fellow European Pharmas With Major US Investment - Citeline News & Insights","headline":"UCB Follows Fellow European Pharmas With Major US Investment - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBzOUZ6LTBmZGIyTGgtMVZ1LVNFUWlCSy1hcXB0eUJNQTZndHdHZ05Od0lSUGtxYkhqMVpqc256dWJYREtHMjUyRlpyWV9TcHJfLUNSY3I5aHZHLWZqMmpkb1VOdFJSMDlZelE?oc=5","date":"2025-03-12","type":"pipeline","source":"Wiley Online Library","summary":"Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome - Wiley Online Library","headline":"Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome","sentiment":"neutral"},{"date":"2022-03-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNN0tFV0JVNGRKV09RUmdCNGhxREtlbFk2ZDdZcFc4WnZILU1yRzRVSzYtaFRJMEM2bVo5eHVYQWNSNFVETHpxamVJYXhLZ0JvSWhoZ2EwZG5LeGFuYzh6NEVVaHR4R1JYOGR0RmtIVHRKUEZLSGhDeEUyQS1JUXkxSzNaa1BRR1A5?oc=5","date":"2022-03-08","type":"pipeline","source":"Pharmaceutical Technology","summary":"UCB concludes acquisition of biopharma firm Zogenix for $1.9bn - Pharmaceutical Technology","headline":"UCB concludes acquisition of biopharma firm Zogenix for $1.9bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQREZldGE4bVAwVUt3MFByeWYtOG1UekNZdmJONUEzWTkwR21sdE9LZmw4aGtQV2d2a3hsd01wWGZ5SXJmTGZCQTRCYWwyS09zcWNtUmZvNWMtZEwyTEZla1BUaFZ6blFZUHppeDRET0otMXpaWHVWZGNxalRVUXREclA4NjZKMjhUY3M2TlY4RlVWeUJXTkppV3FBZmo?oc=5","date":"2022-03-07","type":"pipeline","source":"PR Newswire","summary":"UCB Completes Acquisition of Zogenix, Inc. - PR Newswire","headline":"UCB Completes Acquisition of Zogenix, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcXRsOTFpWVBBRndrdmNWaDJzc2tjajB3SVZHa0h4cmNsQVo4V3F4V2MxZEthUjdTeW1MbWVhMk5hWjkwRUZycDEyV0cwZnlJLXc4N2M4aEtBYVBrc1RBVHVhZDZLRVEzZVNsZXNEbUQ3dC1ZZ2c1bEw1RUdwV3JXbkRHT1lhUnEtOTVN?oc=5","date":"2022-01-20","type":"pipeline","source":"Yahoo Finance","summary":"Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB - Yahoo Finance","headline":"Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOOTdwMEpWQ0l6b1VvdVhVUGh5LV9xYllEaFJmeE9YdGI5U29kdUx6b3prWmJYd0haNHdjQU1TNmdrM2FJR2dQbWpiM0Z1UE5KbDc1Und6c1kxRmVZSzRHeWdoa3dValNoRnhkdXZndlRRYUd0RHZqcldtUmwyemt0NHBCRFFybjNXOUkxXzhBbjNtaHIySzBkNGx4LWNYQXNRTGkyVlFra0l5Z3JxLThiN0FDanBIcGhv?oc=5","date":"2022-01-19","type":"deal","source":"Fierce Pharma","summary":"UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy position - Fierce Pharma","headline":"UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy position","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPV1FlU1pSY3dSNU9ZS2xhNEtyV08taC04TnFHYnAwM2ZfQWxRWS15YWlkLU9MT3hsTFpNREFfejY3U0trcnZac0xvRnFMTlhhbk9ELVBZeW5UcW9La2NZcGVOSWhxTklveGpwVFJDZEpLTVFmWVc3cnliZ09ZYktrQ1dXRE9hYWNKblo3WVZFTnpVZjRvNngtR29YZnc1QTN5cmxZc0FXcGJZVXVhb1JEa2ZPbnhHZkV4M1VZeEpURmZxOFl6YTEtREFIUQ?oc=5","date":"2022-01-19","type":"deal","source":"Reuters","summary":"Epilepsy drug maker Zogenix soars on UCB's potential $2 bln deal - Reuters","headline":"Epilepsy drug maker Zogenix soars on UCB's potential $2 bln deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNkNqa19QYXE5OXRMRThFdVVrSmVOT1l0Zlo1ank3UnVIbVNCWkZzLTRSRFJPaFY0QXFRME1xcXQtbm1pVU4tRENqRlpiR2RLZ184RWlfckRPMkowdlJ3TWItZ05KQlBwbkVPYlEzQWRtZThHVnB4R3hKYWpIQzl4dDRoSnd4b1pOeFBnZFNsajhSVUhGTnhvMDFzcUFtNlFlai1fY3pB?oc=5","date":"2022-01-19","type":"pipeline","source":"BioWorld News","summary":"UCB offers $1.9B for Zogenix and its rare epilepsy drug Fintepla - BioWorld News","headline":"UCB offers $1.9B for Zogenix and its rare epilepsy drug Fintepla","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPN05zekVmZy0wWUdMOVZhaFoySkNuZ0hraUNiT1BLSXdkRXlvTlZzdU1sTVVxak5nbmhST1V3MkFTLVJVMXBrTHp2LU92RUJRc1JuNkcwODBqMjFwckdGaXZ1emtDc19PMzMyNUFBVU9la0plQWFYanNDWHZCa09qVjZDR2ZRcWx5?oc=5","date":"2022-01-19","type":"deal","source":"BioPharma Dive","summary":"UCB to buy Zogenix for nearly $2B in ‘first step’ for M&A in 2022 - BioPharma Dive","headline":"UCB to buy Zogenix for nearly $2B in ‘first step’ for M&A in 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOQ3NxZkJPM3lWSGpOVXNnTG95Z01QVGU2OUcwQU5TNHRoal9sOVN0bDBYSUNzZndxRFFITlM4QnVQN2ViUmpFZkZYY2JFNHZlbkpVbi1oQW5ZcDAwallGcTBtN0JrRzlJbmVlbWlTZFJrQVQ3RVF2UVRaTzVneEEwWGU0WnhRNnhOVnBXcUlRR0FGZw?oc=5","date":"2021-01-26","type":"pipeline","source":"clinicalleader.com","summary":"Zogenix Puts Focus On Safety In Seizure Patients - clinicalleader.com","headline":"Zogenix Puts Focus On Safety In Seizure Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPRWlrbXl3YU0tcGhyYm5TRjhNSHhPSXRTM1RZbTZFdVRxcTNJcFdRa0NUbmhENjNocHh1MEw1N1k2SW14aUpnN2czRjdYdWdhVkdERk9obTRSRFZBWHBIY25FZk44Y1RYSEtqdzhqU0R6NGItd1JPQ1N0a19jVmNBMG1uYlhmbTUzSUlIak5SelctMV9Qa2pKY0xRU3JDWV8xNEZsOGZZYjZRbEtxMUtRSno3OEttZU5uV0p6S0hKOTJINTItSXVhZTdobXRLdUtTWDBaYkVRamduU1V1YUpxMHJkWmV5T1U4VzlaZzVzWDdkdGt1WE9oUFpR?oc=5","date":"2019-03-19","type":"pipeline","source":"GlobeNewswire","summary":"Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan - GlobeNewswire","headline":"Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOZHNCa3BiZUhoQWJlY2FWR19zTDZBNWFUQnJsZjNIekxNZGt5N19RNDNFMVIzYmJtOXlOVVYxdS12bnMzYTNQZWpLZ09ybFdxckNMNUZkR3NZUjZZNHJJU3VOdmNZTGd6eDdSN09qcmFIbE1aMUFYeXRPb1VzMUZDQS1UQQ?oc=5","date":"2013-12-23","type":"pipeline","source":"Contract Pharma","summary":"Zogenix Expands Leadership Team - Contract Pharma","headline":"Zogenix Expands Leadership Team","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":81690000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":81690000,"period":"2021-12-31"},{"value":13643000,"period":"2020-12-31"},{"value":13643000,"period":"2020-12-31"},{"value":3648000,"period":"2019-12-31"},{"value":3648000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":0,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-227413000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":468489000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}